Efavirenz
- Generic Name
- Efavirenz
- Brand Names
- Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C14H9ClF3NO2
- CAS Number
- 154598-52-4
- Unique Ingredient Identifier
- JE6H2O27P8
- Background
Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...
- Indication
For use in combination treatment of HIV infection (AIDS)
- Associated Conditions
- Human Immunodeficiency Virus Type 1 (HIV-1) Infection
- Associated Therapies
- -
A Clinical Trial Comparing the Efficacy of Tenofovir Disoproxil Fumarate/Emtricitabine/Rilpivirine (TDF/FTC/RPV) Versus TDF/FTC/Efavirenz (TDF/FTC/EFV) in Patients With Undetectable Plasma HIV-1 RNA on Current First-line Treatment
- Conditions
- Interventions
- First Posted Date
- 2012-10-17
- Last Posted Date
- 2021-02-11
- Lead Sponsor
- Janssen-Cilag International NV
- Target Recruit Count
- 426
- Registration Number
- NCT01709084
Pharmacokinetic Study of Pitavastatin and Ritonavir-Boosted Darunavir or Efavirenz
- Conditions
- Interventions
- First Posted Date
- 2012-09-28
- Last Posted Date
- 2020-08-11
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 34
- Registration Number
- NCT01695954
- Locations
- 🇺🇸
Bellevue/NYU AIDS Clinical Trials Unit, New York, New York, United States
BREATHER (PENTA 16) Short-Cycle Therapy (SCT) (5 Days on/2 Days Off) in Young People With Chronic HIV-infection
- First Posted Date
- 2012-07-16
- Last Posted Date
- 2015-03-02
- Lead Sponsor
- PENTA Foundation
- Target Recruit Count
- 160
- Registration Number
- NCT01641016
- Locations
- 🇮🇪
Our Lady's Children's Hospital, Dublin, Ireland
🇹🇭Program for HIV Prevention and Treatment (PHPT)/IRD 174, Changklan, Muang, Chiang Mai, Thailand
🇫🇷INSERM, Villejuif, France
Comparing PI-Based to a nNRTI-based ART for Clearance of Plasmodium Falciparum Parasitemia in HIV-Infected
- First Posted Date
- 2012-07-03
- Last Posted Date
- 2019-08-06
- Target Recruit Count
- 52
- Registration Number
- NCT01632891
- Locations
- 🇰🇪
AMPATH at Moi Univ. Teaching Hosp. Eldoret CRS (12601), Eldoret, Kenya
🇰🇪Walter Reed Project - Kenya Med. Research Institute Kericho CRS (12501), Kericho, Kenya
🇲🇼College of Med. JHU CRS (30301), Blantyre, Malawi
A Dose-Ranging Study to Compare Doravirine (MK-1439) Plus TRUVADA® Versus Efavirenz Plus TRUVADA® in Human Immunodeficiency Virus (HIV)-1 Infected Participants (MK-1439-007)
- Conditions
- Interventions
- First Posted Date
- 2012-07-02
- Last Posted Date
- 2019-07-18
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 342
- Registration Number
- NCT01632345
Evaluating the Response to Two Antiretroviral Medication Regimens in HIV-Infected Pregnant Women, Who Begin Antiretroviral Therapy Between 20 and 36 Weeks of Pregnancy, for the Prevention of Mother-to-Child Transmission
- Conditions
- Interventions
- First Posted Date
- 2012-06-13
- Last Posted Date
- 2020-01-30
- Lead Sponsor
- Westat
- Target Recruit Count
- 408
- Registration Number
- NCT01618305
- Locations
- 🇹🇭
Siriraj Hospital ,Mahidol University NICHD CRS, Bangkok, Bangkoknoi, Thailand
🇹🇭Bhumibol Adulyadej Hospital, Bangkok, Thailand
🇧🇷Hospital Nossa Senhora da Conceicao NICHD CRS, Porto Alegre, Rio Grande Do Sul, Brazil
A Study of Potential Drug-Drug Interaction Between Efavirenz and Danoprevir With Low Dose Ritonavir in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2012-04-30
- Last Posted Date
- 2016-11-02
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 40
- Registration Number
- NCT01588002
Efavirenz Versus Rilpivirine on Vascular Function, Inflammation, and Oxidative Stress
- First Posted Date
- 2012-04-25
- Last Posted Date
- 2015-08-14
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 40
- Registration Number
- NCT01585038
- Locations
- 🇺🇸
Indiana Clinical and Translational Sciences Institute, Indianapolis, Indiana, United States
Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
- First Posted Date
- 2012-01-25
- Last Posted Date
- 2017-07-19
- Lead Sponsor
- Janssen-Cilag G.m.b.H
- Target Recruit Count
- 312
- Registration Number
- NCT01516970
The Neurocognitive Sub-study of Encore1
- First Posted Date
- 2012-01-24
- Last Posted Date
- 2013-09-19
- Lead Sponsor
- Kirby Institute
- Target Recruit Count
- 71
- Registration Number
- NCT01516060
- Locations
- 🇹🇭
HIVNAT Research Collaboration, Bangkok, Thailand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.